DEA Hearing Tests cannabis rescheduling Proposal
DEA hearing on cannabis rescheduling draws seven opposition groups; FDA witness defends 252-page HHS analysis, two-part CAMU test, and 2023 recommendation.
Cannabis news, weed news, marijuana news
DEA hearing on cannabis rescheduling draws seven opposition groups; FDA witness defends 252-page HHS analysis, two-part CAMU test, and 2023 recommendation.
Cannabis rescheduling prompts two companies to intervene in federal lawsuits; Congress files IBOGAINE Act; states update zoning and medical cannabis access.
Opponents present witnesses and evidence at DEA hearing on marijuana rescheduling, starting June 29 and running through July 15; DEA bars supporters and
DOJ reclassifies medical cannabis to Schedule III April 23, opening DEA registration, easing 280E tax limits, and changing Nevada research, sales, and
cannabis rescheduling hearing starts June 29; DEA named seven opposing parties and excluded rescheduling advocates. Judge Derek Julius presides through
In response to delays in the marijuana rescheduling process that began under the previous presidential administration, congressional researchers assert that…
Veterans returning from military service often face significant challenges, including anxiety, chronic pain, and post-traumatic stress disorder (PTSD). After serving…
The effort to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act faces significant hurdles, according…
The Drug Enforcement Administration (DEA) has released its 2025 National Drug Threat Assessment (NDTA) Report, which raises doubts about the…
Cannabis companies may not need to wait for federal rescheduling to escape the burdensome 280E tax penalties that prevent them…